Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity

Bibliographic Details
Main Author: Camões-Barbosa, A
Publication Date: 2019
Other Authors: Ribeiro, I, Medeiros, L
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.10/2331
Summary: Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.
id RCAP_f2b881c83eb863872f8b54bd1ba9a971
oai_identifier_str oai:repositorio.hff.min-saude.pt:10400.10/2331
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke SpasticityParesia do Membro Superior Contralateral Após Infiltração de Toxina Botulínica A para Espasticidade Pós-AVCBotulinum toxins type AMuscle weaknessBotulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.Ordem dos MédicosUnidade Local de Saúde Amadora / SintraCamões-Barbosa, ARibeiro, IMedeiros, L2019-12-05T11:51:05Z20192019-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.10/2331eng1646-075810.20344/amp.11503info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-03-10T15:01:48Zoai:repositorio.hff.min-saude.pt:10400.10/2331Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-29T01:15:13.218193Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
Paresia do Membro Superior Contralateral Após Infiltração de Toxina Botulínica A para Espasticidade Pós-AVC
title Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
spellingShingle Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
Camões-Barbosa, A
Botulinum toxins type A
Muscle weakness
title_short Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_full Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_fullStr Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_full_unstemmed Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
title_sort Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity
author Camões-Barbosa, A
author_facet Camões-Barbosa, A
Ribeiro, I
Medeiros, L
author_role author
author2 Ribeiro, I
Medeiros, L
author2_role author
author
dc.contributor.none.fl_str_mv Unidade Local de Saúde Amadora / Sintra
dc.contributor.author.fl_str_mv Camões-Barbosa, A
Ribeiro, I
Medeiros, L
dc.subject.por.fl_str_mv Botulinum toxins type A
Muscle weakness
topic Botulinum toxins type A
Muscle weakness
description Botulinum toxin type A has been approved for spasticity management in poststroke patients. The adverse effects are generally of two types: those related to local injection; and those related to the systemic effects from spread of the toxin. Contralateral weakness after botulinum toxin A treatment is a rarely reported adverse effect. We report the case of a 33-year-old female who had been receiving regular injections of incobotulinum toxin A due to spasticity of the right limbs after a hemorrhagic stroke. A switch was made to abobotulinum toxin A with an overall conversion ratio of 1:3.83. The patient presented contralateral upper limb paresis, especially of the deltoid muscle, in the second week post-injection. The electroneuromyography showed neuromuscular block due to botulinum toxin A. She recovered completely after eight months. A switch between different formulations of botulinum toxin type A should prompt caution when carrying out unit conversions. Distant side effects may appear, including paresis in the contralateral limbs.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-05T11:51:05Z
2019
2019-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.10/2331
url http://hdl.handle.net/10400.10/2331
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1646-0758
10.20344/amp.11503
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833600893265641472